The CCR2 Inhibitor Propagermanium Attenuates Diet-Induced Insulin Resistance, Adipose Tissue Inflammation and Non-Alcoholic Steatohepatitis (original) (raw)
Fig 4
Effects of propagermanium intervention on NASH development.
(A) HFD feeding induced pronounced macrovesicular steatosis, which was reduced in HFD+Pro_6w group. (B) Microvesicular steatosis was induced by HFD and was not affected by propagermanium treatment. (C) Quantification of the number of inflammatory cell aggregates per field in the liver (lobular inflammation), which was increased by HFD and tended to be reduced by early propagermanium treatment. (D) Lobular inflammation strongly correlates with the ratio of M1/M2 markers (CD11c/Arginase-1 gene expression). (E) M1/M2 ratio is decreased by propagermanium treatment, indicating a shift towards M2 phenotype. All data are mean±SEM. * _p<_0.05.